FDA Confirms GLP-1 RA Safety Review: No Increas...

By HEOR Staff Writer

February 2, 2026

GLP-1 RA Safety Review Clears Suicidal Risk Concerns In a pivotal GLP-1 RA safety review, the U.S. Food and Drug Administration (FDA) has concluded, following an extensive analysi...
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Thro...
WHO Guidelines Set New Standard for GLP-1 Obesity Therapies in Adults
Weight Loss: Advances in Hormone-Based Obesity Treatments
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss...
Obesity Health Economics: Forecasting Trends and Costs in the US
Evolving Burden of Obesity in the US: Key Insights on Obesity Prevention Stra...
Insights on GLP-1 Therapy in Bariatric Surgery Patients
Impact of Generic Liraglutide Launch on Weight Management and Health Economics
Mounjaro Price Increase UK: Impacts on Access and Health Economics
Evolving Strategies in Type 2 Diabetes Management: NICE Guideline Update 2025
NICE’s 2025 Guidance on Obesity Management Support